Hypochlorite modified LDL are a stronger agonist for platelets than copper oxidized LDL  by Volf, Ivo et al.
Hypochlorite modi¢ed LDL are a stronger agonist for platelets than
copper oxidized LDL
Ivo Volf*, Astrid Roth, Julian Cooper, Thomas Moeslinger, Elisabeth Koller
Institute of Physiology, Schwarzspanierstr. 17, A-1090 Vienna, Austria
Received 21 September 2000; accepted 25 September 2000
Edited by Pierre Jolles
Abstract Experimental low density lipoprotein (LDL) oxida-
tion is usually performed using trace copper, although the in vivo
relevance of this method has been called into question. Such LDL
augment adenosine 5P-diphosphate (ADP) induced platelet
aggregation, presumably by the action of lipid derived
compounds. In striking contrast, we find that LDL oxidized to
a comparable extent by hypochlorite, an in vivo occurring
oxidant, reveal themselves to be potent promoters of platelet
aggregation. Interestingly, hypochlorite modified LDL seem to
mediate their influence on human platelets by means of the
modified apolipoprotein B-100 (apoB) moiety. Also, the finding
that hypochlorite modified albumin is able to trigger platelet
aggregation suggests an essential role for hypochlorite modified
protein(s) in the process of platelet activation. ß 2000 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Oxidative modi¢cation dramatically changes the biologic
properties of low density lipoprotein (LDL), converting
them into a form that is both atherogenic and pro-thrombotic
[1^3].
A hallmark of LDL oxidation is the loss of speci¢city to the
apolipoprotein B-100 (apoB) receptor and the emergence of
speci¢city to the so-called scavenger receptor (SR) [4]. Con-
trary to the expression of the apoB receptor, this receptor is
not down-regulated by increased intracellular cholesterol lev-
els. Thus incubation of macrophages with modi¢ed LDL leads
to an unregulated cellular uptake of lipoproteins and results in
massive cholesterol deposition within the cells. As macro-
phages incubated in this way demonstrate a striking similarity
to foam cells, which are characteristic of atherosclerotic le-
sions, it was concluded at an early date that SRs might play
a decisive role in the development of atherosclerosis (for re-
view see [5]).
The formation of high uptake LDL is generally held to be
preceded by, and to some extent caused by, peroxidation of
the LDL lipid moiety, a process which also results in the
formation of numerous lipid derived bioactive compounds.
In fact, of the numerous e¡ects attributed to oxidized LDL
(OxLDL) (e.g. cytotoxicity [6], chemotaxis [7] or the impair-
ment of di¡erent nitric oxide synthase isoforms [8,9]), many
seem to be mediated by such lipid derived compounds rather
than by direct SR binding of the apoB moiety and subsequent
downstream signaling.
Experimentally, LDL oxidation in vitro is usually per-
formed by incubating the lipoproteins with trace copper.
Although copper (as well as iron) has been shown to be
present in atherosclerotic lesions [10], the signi¢cance of trace
metal mediated LDL oxidation in vivo has been called into
question (recently discussed in review [11]).
In fact, there is little knowledge about the prevalent oxida-
tion mechanism(s) taking place in vivo. At present, direct
evidence for the involvement of particular oxidants in (sub-
endothelial) LDL modi¢cation is limited to lipoxygenase
[12,13], peroxynitrite [14], oxygen centered radicals [15] and
hypochlorite [15^17]. Among these, hypochlorite is of special
interest as LDLs modi¢ed by this agent elementarily di¡er
from LDL oxidized via other pathways. In particular, it has
been shown that LDL modi¢cation by hypochlorite results in
almost exclusive modi¢cation of the apoB moiety without
inducing the formation of signi¢cant amounts of lipid perox-
ides [18]. Beside semi-stable chloramines, chlorinated deriva-
tives of tyrosine are formed as a speci¢c consequence of hy-
pochlorite interaction with proteins and the identi¢cation of
chlorinated tyrosine in atherosclerotic lesions provides clear
evidence for the in vivo existence of hypochlorite modi¢ed
(lipo)proteins (reviewed in [19]). Furthermore, monoclonal
antibodies against hyp-OxLDL (LDL oxidized by HOCl/
OCl3) have been raised that show speci¢city for parts of
human atherosclerotic lesions; nevertheless, these antibodies
do not cross-react with copper oxidized LDL [16]. Therefore,
LDL modi¢cation by hypochlorite results in lipoproteins that
elementarily di¡er from conventional experimentally used
copper oxidized LDL and results obtained with this lipopro-
tein species might have higher in vivo relevance than those
obtained with conventionally used copper oxidized LDL.
2. Materials and methods
Carrier-free Na125I was purchased from ICN (Costa Mesa, CA,
USA). Maleylated human serum albumin (M-HSA) was prepared as
originally described for bovine albumin [20]. Essentially fatty acid-free
human albumin was purchased from Sigma (Vienna, Austria). Elec-
trophoretic mobility of native and modi¢ed LDL under non-denatur-
ing conditions was assessed by agarose electrophoresis [21]. Thiobar-
bituric acid reactive substances (TBARS) were assessed as described
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[22]. NaOCl was from Sigma-Aldrich (Vienna, Austria) and was
standardized at 290 nm using a molar extinction coe⁄cient of 350
M31 cm31 [23] and freshly diluted in phosphate bu¡ered saline.
2.1. Lipoproteins
Each step was performed at 4‡C and ethylenediaminetetraacetic
acid (EDTA) was added to all solutions (except preceding copper
oxidation), resulting in a ¢nal concentration (f.c.) of 0.1 mM, to
prevent inadvertent oxidation by trace metal ions. Lipoproteins
were used immediately after preparation. Native LDL were rebu¡ered
immediately before use (100 mM borate bu¡er, 0.1 mM EDTA, 50
mM NaCl, pH 7.3). Unless otherwise stated, rebu¡ering was per-
formed by gel ¢ltration (Econo-Pac 10DG Columns, Bio-Rad, CA,
USA).
Concentrations of lipoproteins are expressed in terms of their pro-
tein content as determined by the Lowry method [24].
2.2. Preparation of native LDL
LDL were isolated from normal human plasma (anticoagulated
with 1/10 volume of 3.8% (w/v) trisodium citrate) immediately after
blood sampling by sequential centrifugation at 100 000Ug in the den-
sity range d = 1.019^1.063 g/ml [25]. After £otation, the lipoproteins
were ¢ltered (0.45 Wm).
2.3. Oxidation of LDL
LDL oxidation by copper ions was performed according to a com-
monly used protocol. After exhaustive dialysis of LDL against borate
bu¡er (100 mM, pH = 7.2), the LDL (at a concentration of 200^250
Wg/ml) were incubated with CuSO4 (f.c. 5 WM) at 37‡C in the same
bu¡er. After 24 h the incubation was stopped and the lipoproteins
were concentrated to approximately 2 mg/ml using ultrafree-15 units
with a molecular weight cut-o¡ of 100 000 (Millipore, Vienna, Aus-
tria). Subsequently, OxLDL were rebu¡ered (100 mM borate bu¡er,
0.1 mM EDTA, 50 mM NaCl, pH 7.3). REM of copper oxidized
LDL was 1.95 þ 0.2 (n = 5). Preliminary studies showed that the elec-
trophoretic mobility increased over the 24 h of incubation at 37‡C,
although the resulting increase in REM remained the same even when
copper concentrations were varied between 1 WM and 20 WM.
Hypochlorite modi¢cation of LDL was basically performed accord-
ing to Arnhold et al. [26]. In brief, native LDL were transferred to
sodium borate bu¡er (100 mM, containing 0.1 mM EDTA, pH = 7.2).
At 0‡C, HOCl/NaOCl was added to LDL while rapidly and gently
mixing. There was a direct linear correlation between the amount of
oxidant used and the electrophoretic mobility of the resulting hypo-
chlorite modi¢ed LDL. For the comparative studies described herein,
the amount of hypochlorite for LDL oxidation was chosen such that
the same electrophoretic mobility was achieved as LDL from the same
donor oxidized by copper. As a result, an approximately 300-fold
molar excess of hypochlorite over LDL was employed. After 15
min, the possibly remaining oxidant was removed by gel ¢ltration
(100 mM borate bu¡er, 0.1 mM EDTA, 50 mM NaCl, pH 7.3).
Hyp-OxLDL were always stored on ice and used within 1 week.
2.4. Reversibility of LDL modi¢cation
Two hours after hypochlorite modi¢cation, the lipoproteins were
treated with the indicated amounts of ascorbate. After 10 min at room
temperature, the lipoproteins were rebu¡ered.
2.5. Radioiodination
Radioiodination of LDL was performed by the Iodo Bead method
using N-chloro-benzenesulfonamide conjugated polystyrene beads
(Pierce, Rockford, IL, USA) following the manufacturers instructions.
The speci¢c radioactivity of the labeled OxLDL species ranged from
150 to 250 cpm/ng protein.
2.6. Isolation of human platelets
Human platelets were isolated from freshly drawn blood as previ-
ously described [27]. Brie£y, blood was anticoagulated with 1/10 vol-
ume of 3.8% (w/v) trisodium citrate and centrifuged immediately at
120Ug for 20 min to yield platelet-rich plasma. Prostacyclin (PGI2)
was added at a f.c. of 25 Wg/l. Platelets were pelleted at 800Ug for
5 min and resuspended with Tyrode bu¡er without Ca2 (137 mM
NaCl, 2.7 mM KCl, 11.9 mM NaHCO3, 1.0 mM MgCl2, 0.42 mM
NaH2PO4, 5.5 mM D-glucose, 3.5 g/l human serum albumin, 25 Wg/l
PGI2, pH 6.5). This washing procedure was repeated twice and ¢nal
resuspension of the platelet pellet was performed with Tyrode bu¡er
containing 2 mM CaCl2, pH 7.35, without PGI2. After isolation, the
platelet suspension was immediately chilled on ice for at least 30 min
before performing the binding assays or kept at room temperature for
aggregation studies.
2.7. Aggregation studies
Platelet aggregation was determined in a 490-4D four-channel ag-
gregometer (Chronolog Corp., Havertown, PA, USA). Transmission
was measured between 0% and 100% based on values obtained with
platelet suspension and suspension medium, respectively. Platelet sus-
pensions (adjusted to 2U105 cells/Wl in a ¢nal volume of 0.5 ml) were
supplemented with puri¢ed human ¢brinogen (0.2 g/l, f.c.) and human
albumin (3.5 g/l, f.c.). Suspensions were stirred for 3 min in siliconized
glass cuvettes in the aggregometer (without further additions or with
M-HSA) before adding the aggregating agents. As a control, adeno-
sine 5P-diphosphate (ADP) induced aggregation (5 to 30 WM) was
performed and the experiments were discontinued after the ¢rst de-
cline of reactivity was observed.
2.8. Binding and competition studies
Binding and competition studies were performed on ice due to the
extreme potency of hyp-OxLDL in triggering platelet aggregation.
Albumin was present throughout the incubation procedure (2 h) at
a concentration of 0.1%. After incubation with the labeled lipopro-
teins, platelet suspensions were centrifuged through a prechilled 1:3
dilution of Ficoll-Paque (Amersham Pharmacia Biotech, Uppsala,
Sweden) in saline. The supernatants (containing the unbound lipopro-
tein fraction) were aspirated and the tips containing the pellets (con-
taining the platelet bound LDL fraction) were cut o¡ using a hot wire
[27].
Bound and unbound fractions were counted in a Cobra II gamma
counter (Canberra Industries, Meriden, CT, USA).
Non-speci¢c binding was determined by adding a 20-fold excess of
the respective unlabeled LDL to the incubation mixture and was
usually between 10% and 20% of total binding.
All experiments were performed with LDL from at least three dif-
ferent donors. Results are expressed as mean values þ standard devia-
tion (S.D.) of at least four experiments. Aggregation studies were
performed with platelets from ¢ve di¡erent donors the results of
which were basically identical. Aggregation tracings shown in Figs.
3 and 4 represent the results of two such experiments.
3. Results and discussion
Oxidatively modi¢ed LDL have been implicated in the de-
velopment of atherosclerosis, a disease that is accompanied by
platelet hyperreactivity and severe thrombotic disorders.
These e¡ects on platelets could also in part be the result of
a direct interaction between oxidized LDL and human plate-
lets, as OxLDL have been shown to stimulate human platelets
in vitro [28^37]. As most studies dealing with the interaction
of OxLDL and human platelets have been performed with
copper oxidized LDL, it was the aim of this work to study
the in£uence on human platelets of hyp-OxLDL, a presum-
ably naturally occurring form of LDL modi¢cation, and to
directly compare the results with those obtained with copper
oxidized LDL.
Incubation of native LDL with trace copper following a
commonly used protocol (see Section 2) resulted in an approx-
imately 2-fold increase of the electrophoretic mobility of the
lipoproteins (REM = 1.95 þ 0.2, n = 5) and signi¢cant accumu-
lation of TBARS (9.25 þ 2.5 vs. 0.45 þ 0.15 nmol/mg for native
LDL, n = 5). Treatment of LDL with reagent hypochlorite
resulted in an increase of the electrophoretic mobility of
hyp-OxLDL that was strictly dependent on the amount of
hypochlorite added (not shown). In contrast to oxidation by
trace copper, LDL modi¢cation by hypochlorite did not result
in the formation of TBARS, which is in accordance with
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recently published results [26]. In order to obtain adequate
data for the comparison of Cu-OxLDL (copper oxidized
LDL) and hyp-OxLDL, hypochlorite was added to native
LDL such that the REM values were virtually identical to
those obtained with Cu-OxLDL (see Section 2).
As shown in Fig. 1, apoB modi¢cation (measured as REM)
of hyp-OxLDL [18,38], but not that of Cu-OxLDL, can be
reversed in a dose dependent way by the subsequent addition
of ascorbate, although high levels of antioxidant are needed
for the reversal of such a high degree of modi¢cation. The
time frame in which the reversibility of hypochlorite modi¢-
cation of LDL was possible covered a period of several days
from the moment of modi¢cation onward, provided that the
hyp-OxLDL were constantly stored at 4‡C.
Binding experiments revealed that both hyp-OxLDL and
Cu-OxLDL show speci¢c and saturable high a⁄nity binding
to the membrane of human platelets with virtually identical
a⁄nities (Kd = 5.75 þ 0.45 Wg/ml and 6.04 þ 0.2 Wg/ml for Cu-
OxLDL and hyp-OxLDL, respectively). As depicted in Fig. 2,
binding of both modi¢ed LDL species is not in£uenced by
either native LDL or fucoidan (a selective inhibitor of OxLDL
binding to class A SRs). In contrast, M-HSA, an inhibitor of
OxLDL binding to all currently classi¢ed SRs, reduces lipo-
protein binding to background values. These results indicate
an exclusive involvement of receptors with properties of class
B SRs in the binding of both lipoprotein species, which is in
accordance with previously published results obtained with
Cu-OxLDL [39].
Despite similar binding and competition patterns, hyp-
OxLDL and Cu-OxLDL dramatically di¡er with regard to
their impact on platelet function. As shown in Fig. 3, Cu-
OxLDL, despite being able to augment ADP induced platelet
aggregation, are not capable of independently triggering an
aggregation response (investigated to f.c. of 1 mg/ml). In con-
trast, hyp-OxLDL modi¢ed to a comparable extent, reveal
themselves to be potent promoters of platelet aggregation
(Fig. 3, tracing (f)). In fact, the impact of hyp-OxLDL on
platelet function turns out to be far stronger than that of
any other LDL modi¢cation reported thus far, as ¢nal lipo-
protein concentrations of approx. 20 Wg/ml are su⁄cient to
achieve a maximal aggregation response (not shown). The
cyclooxygenase pathway is obviously not involved in platelet
aggregation triggered by hyp-OxLDL, as acetylsalicylic acid is
not able to reduce this e¡ect. In contrast, both PGI2 and
theophylline are able to impair this type of aggregation re-
Fig. 2. Speci¢c binding of radioactive labeled oxidized LDL (10 Wg/
ml) to human platelets in the presence of native LDL (200 Wg/ml),
fucoidan and M-HSA (50 Wg/ml each). Data represent the mean of
four experiments in duplicate þ S.D.
Fig. 3. In£uence of hyp-OxLDL and Cu-OxLDL on platelet aggre-
gation: (a) Cu-OxLDL, (b) ADP, (c) Cu-OxLDL+ADP, (d) Cu-
OxLDL+ADP in the presence of M-HSA (50 Wg/ml); f.c. for Cu-
OxLDL and ADP were 100 Wg/ml and 10 WM, respectively. (e) Hy-
pochlorite modi¢ed albumin (f.c. 100 Wg/ml, 100-fold molar excess
of NaOCl over albumin), (f) hyp-OxLDL (15 Wg/ml, 300-fold molar
excess of NaOCl over LDL), (g) hyp-OxLDL (10 Wg/ml, 400-fold
molar excess of NaOCl over LDL).
Fig. 1. Relative electrophoretic mobility of hyp-OxLDL and Cu-
OxLDL after treatment with the indicated amounts of ascorbate.
Each data point represents the mean of ¢ve experiments (with LDL
from di¡erent donors) þ S.D.
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sponse in a dose dependent manner (not shown), therefore
ruling out the possibility that the observed e¡ects result
from agglutination of platelets.
Regarding LDL modi¢ed by copper and other means, sen-
sitization of human platelets by oxidatively modi¢ed LDL has
been reported in most cases but contradictory reports exist as
to whether these lipoproteins are able to independently trigger
platelet aggregation [28^31] or not [32^37].
In cases where a self-aggregatory e¡ect has been attributed
to oxidatively modi¢ed LDL, lipoprotein modi¢cation was
achieved by oxidation with copper ions [28^30] and peroxyni-
trite [30], respectively, or by autooxidation [31]. In any case,
the threshold lipoprotein concentration used in the above
cited works for triggering platelet aggregation was at least
160 Wg/ml (f.c.) and up to 2 mg/ml of lipoprotein were re-
quired to achieve maximal aggregation response, which is
some two orders of magnitude higher than the concentrations
obtained here for hyp-OxLDL.
Reports exist that platelet aggregation can be evoked by
minimally modi¢ed LDL (presumably due to lipid mediators
capable of stimulating human platelets) and that lipoproteins
do not possess this biologic property when fully oxidized
[30,31]. Interestingly, such an inverse correlation between
the degree of lipoprotein oxidation and platelet stimulatory
e¡ects obviously is not true for LDL modi¢cation by hypo-
chlorite, as the modi¢ed lipoproteins used in the present work
clearly represent heavily oxidized LDL (displaying an approx.
2-fold increase in their REM). A further increase of the molar
excess of hypochlorite over LDL results in greater electropho-
retic mobility of the resulting LDL and this is accompanied by
a higher potency for stimulating human platelets (see Fig. 3,
tracing (g)). On the other hand, lipoproteins displaying a low-
er degree of apoB modi¢cation ^ as a result of using lower
amounts of hypochlorite (not shown) or following subsequent
treatment with ascorbate ^ are consequently less potent in
triggering platelet aggregation (shown in Fig. 4, tracings (a)^
(e)).
Thus, the close relationship between the extent of apoB
modi¢cation and the capability of hyp-OxLDL to trigger
platelet aggregation might be an argument for an essential
role of the hypochlorite modi¢ed apoB moiety in this process
of platelet activation. The hypothesis that protein modi¢ca-
tion by hypochlorite can result in the acquisition of platelet
stimulatory properties is also strengthened by the ¢nding that
even hypochlorite modi¢ed albumin is able to trigger platelet
aggregation (depicted in Fig. 3, tracing (e)). Furthermore,
addition of M-HSA in concentrations that are able to block
speci¢c hyp-OxLDL binding to the platelet surface results in a
dose dependent inhibition of platelet aggregation induced by
these lipoproteins (shown in Fig. 4, tracings (f)^(j)). Therefore,
we consider it likely that the e¡ects of hyp-OxLDL on platelet
function arise from modi¢cation of apoB by hypochlorite and
that these e¡ects are a direct consequence of speci¢c binding
of the modi¢ed apoB moiety to the platelet surface. Never-
theless, as seemingly unrelated ligands such as albumin and
LDL acquire platelet stimulatory e¡ects after modi¢cation by
hypochlorite, it should be taken into account that the result-
ing e¡ects might arise from the interaction of semi-stable
chloramines with the platelet surface. As the decomposition
of chloramines is known to result in the formation of free
radicals [40], such decomposition might be accelerated by
exoenzymes located on the platelet surface and might yield
radicals that exert direct in£uence on the reactivity of human
blood platelets.
Apart from the fact that Cu-OxLDL modi¢ed to a compa-
rable extent are not able to trigger an aggregation response,
there are also fundamental di¡erences to hyp-OxLDL regard-
ing the results obtained with ascorbate and M-HSA: treat-
ment of Cu-OxLDL with ascorbate fails to show any e¡ect
on aggregation tracings obtained in the presence of both ADP
and these lipoproteins (not shown). While this lack of in£u-
ence on the aggregation response might be expected as the
electrophoretic mobility of Cu-OxLDL is not in£uenced by
prior treatment with ascorbate, blocking of speci¢c binding
of Cu-OxLDL to the platelet surface by M-HSA also fails
to show any normalizing e¡ect on the observed augmented
aggregation response in the presence of ADP (previously
shown in [37] and depicted in Fig. 3, tracing (d)). These results
are in accordance with the assumption that some types of
oxidized LDL mediate their in£uence on human platelets in-
dependently of speci¢c binding of the apoB moiety, i.e. prob-
ably by means of one or more oxidation derived lipid medi-
ators capable of stimulating human platelets [31,41].
Nevertheless, the ¢nding that the apoB moiety of Cu-
OxLDL apparently fails to exert any e¡ect on platelet func-
tion poses the intriguing possibility that the in vivo occurring
oxidant hypochlorite (but not trace copper) is able to modify
apoB such that upon binding to distinct receptors on the
platelet surface it is able to trigger speci¢c post binding events,
which are responsible for the observed e¡ects.
Although in vivo conditions might result in more complex
modi¢cation of the LDL particle than that obtained with
reagent hypochlorite (e.g. due to the combined action of
HOCl/OCl3 and H2O2 [42] or the formation of peroxynitrite
and free radicals), the results shown here in any case demand
a critical reassessment of the method of choice for experimen-
tal LDL oxidation.
Acknowledgements: The authors wish to dedicate this work to Mrs.
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Fig. 4. Platelet aggregation induced by: hyp-OxLDL (20 Wg/ml, 300-
fold molar excess of NaOCl over LDL) pretreated with ascorbate:
(a) 1.25 mM, (b) 625 WM, (c) 156 WM, (d) 78 WM, (e) 0 WM; hyp-
OxLDL (20 Wg/ml, 300-fold molar excess of NaOCl over LDL) in
the presence of M-HSA: (f) 40 Wg/ml, (g) 20 Wg/ml, (h) 10 Wg/ml, (i)
3 Wg/ml, (j) without M-HSA. Both ascorbate and M-HSA alone did
not in£uence ADP induced platelet aggregation.
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